7
Nov
2022
Tag: oncology
19
Sep
2022
Bionest
ASCO 2022 – Part 1: Redefining Breast Cancer Classification and Treatment
An important new development in breast cancer greatly expands the number of patients who might benefit from HER2-targeting treatment, as shared at ASCO 2022
16
Mar
2020
Bionest
Helping to Bring Precision Medicine to Community Oncology Practices
New technology and business models are emerging to help community hospitals and regional networks more successfully implement precision medicine therapies.
3
Feb
2020
Bionest
Nobel Prize in Medicine Goes to Oxygen-Sensing Research
How cells sense and adapt to oxygen availability plays an important role in anemia, cancer, stroke, infection, wound healing, and myocardial infarction.
25
Nov
2019
Bionest
Driving CAR-T beyond oncology
Several companies and research institutions are developing potential CAR-T treatments for non-cancer indications, from heart disease to viral infection.
11
Nov
2019
Bionest
ESMO 2019: Translating Science into Better Cancer Care
The field of oncology has seen a number of significant advances in recent years. The considerable number of positive reports from the 2019 Congress of the European Society for Medical Oncology (ESMO) last month clearly reflected the meeting’s theme — the translation of scientific advances into better cancer care. AstraZeneca/Merck was one of stars...
21
Oct
2019
Bionest
New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer
Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...
7
Oct
2019
Bionest
New Approvals for Tumor-Agnostic Cancer Treatments — and the Questions They Raise
On August 15, the U.S. Food and Drug Administration granted accelerated approval to Genentech/Roche’s Rozlytrek (entrectinib) for the treatment of adult and adolescent patients with solid tumors that exhibit neurotrophic tyrosine receptor kinase (NTRK) fusions and for whom there are no existing effective treatments. While NTRK fusions are rare, appearing in about 1% of solid...
12
Aug
2019
Bionest
New Excitement About Antibody-Drug Conjugates in Cancer
The ability to target malignant cells without damage to surrounding healthy ones has been a long-sought goal in cancer drug development. Antibody-drug conjugates (ADCs) have been investigated as one such solution aimed at delivering more targeted therapies. ADCs — an approach first envisioned by Paul Ehrlich in the early 20th century — combine the targeting...
29
Jul
2019